Announcement of the Company’s board meeting date to approve 2024Q3 consolidated financial report

Announcement of issue price and banks designated to collect and deposit the proceeds for 2024 cash capital increase

Announcement on behalf of OBIGEN of the Board’s resolution to lift the non-competition restrictions for CEO

Announcement of reference date of cash capital increase and share subscription

OBI receives US FDA Orphan Drug Designation for OBI-992 TROP2 ADC for the treatment of gastric cancer

Announcement of change of accounting officer

Announcement of change of acting spokesperson

Announcement of new appointment of Chief Operating Officer

Announcement of adjustment of an item in the plan of 2018 cash capital increase

Announcement of BOD’s resolution to issue common shares through cash capital increase in 2024